CAMBRIDGE, Mass.--(BUSINESS WIRE)--Kojin Therapeutics Inc., a company developing new targeted therapeutics based on cell state and ferroptosis biology, today announced the appointment of Luba Greenwood as Chief Executive Officer. Greenwood, who has served on Kojin’s board of directors since June 2021, joins Kojin’s co-founder Vasanthi Viswanathan and Chief Scientific Officer Kay Ahn in leading the company’s vision and growing its women-led executive team.
Greenwood is a leading figure in healthcare with vast experience as an executive, company builder, and investor in therapeutics, life sciences, and tech sectors. She has co-founded biotech and digital health companies in immunotherapy, women's health, artificial intelligence and machine learning, and the microbiome space, and as a life sciences and biotech expert, lectures at Harvard University in the School of Engineering and Applied Sciences. Her leadership roles have spanned Roche, Google, and Pfizer and most recently Greenwood served as a Managing Partner at the Dana-Farber Cancer Institute’s venture fund, Binney Street Capital, a venture arm she founded to further Dana-Farber’s mission of developing treatments for incurable cancers.
“With a focus on oncology, immunology, and neurology, I’ve had the privilege to access and witness the latest breakthrough advancements,” said Luba Greenwood, CEO of Kojin Therapeutics. “From the outset, Kojin’s differentiated platform and modality stood apart, and I knew I wanted to be a part of this revolutionary science and the impact it will have on drug discovery. As a board member I was able to get to know Kojin’s approach and the incredible team behind it, and I’m honored to serve as CEO as we move forward and create transformative medicines for patients.”
In June 2021, Kojin launched with a $60 Million Series A to accelerate its drug discovery platform based on its groundbreaking approach to cell state and ferroptosis biology to develop novel, targeted therapeutics. Since then, the company has accelerated its platform and partnerships with a focus on hard-to-treat cancers, immunology, and fibrosis.
“Luba has been a driving force behind Kojin’s mission and growth trajectory. She brings a collaborative leadership style that is especially valuable for early stage biotech companies bringing interdisciplinary science and technology together,” said Stuart Schreiber, co-founder of Kojin Therapeutics. “We now have a very clear indication of where we will prioritize our platform and we’re thrilled to have Luba implementing this vision as she leads our talented team.”
Greenwood is committed to advancing women in biotechnology and has been a recipient of several awards and honors for her work in the community, including the Science Club for Girls Catalyst Award for her commitment to advocating for women in science and technology.
“We're incredibly proud to add Luba to our executive team, especially in an industry where chief women executives remain rare,” said Vasanthi Viswanathan, co-founder and Head of Discovery Biology of Kojin Therapeutics. “Luba is an inspirational leader who personifies a winning combination of values, experience and perspective that will allow her to fully develop Kojin's platform and partnering potential while simultaneously steering our programs into the clinic. It is a privilege to have a partner at the helm who so deeply believes in the founding mission of Kojin -- transforming the lives of patients by developing a completely new category of therapeutics that work by modulating ferroptosis biology.”
Kojin is focused on building out exceptional in-house biology and computational capabilities to rapidly advance its science. Since its launch, the company has more than doubled in size and will be moving into its own headquarters located in Boston's Seaport neighborhood in February 2022. The company is tripling its machine learning efforts and actively looking to hire computational biologists and chemists.
On Sunday, October 17 at 11:30 a.m. Eastern, Greenwood will be moderating a panel at HLTH 2021 to discuss investment trends in patient experience and engagement.
About Kojin Therapeutics, Inc.
Kojin Therapeutics, Inc. is the first biopharmaceutical company using a proprietary approach to cell state and ferroptosis biology to develop novel, targeted therapeutics for diseases of high unmet need. Founded by Stuart Schreiber, Benjamin Cravatt, Stephanie Dougan and Vasanthi Viswanathan, Kojin is accelerating a drug discovery platform that connects complex cell states to known biochemical processes such as ferroptosis, or iron-dependent cell death, and enables development of selective therapies for a broad range of hard-to-treat diseases. To learn more about how Kojin is drugging the ferroptosis-sensitive cell state, visit kojintx.com or follow us on LinkedIn or Twitter @KojinTx.